Reveal In-Office Implants

January 30, 2018 updated by: Medtronic Cardiac Rhythm and Heart Failure

Reveal® In-Office Implants Study

The purpose of this study is to gather evidence about the safety and feasibility of performing the implant procedure for the Reveal Insertable Cardiac Monitor (ICM) in an office or clinic setting rather than the traditional hospital operating room, cardiac catheterization or electrophysiology (EP) laboratory setting.

Study Overview

Study Type

Observational

Enrollment (Actual)

66

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • La Jolla, California, United States
    • Florida
      • Miramar, Florida, United States
    • Georgia
      • Macon, Georgia, United States
    • Indiana
      • Munster, Indiana, United States
    • Maryland
      • Takoma Park, Maryland, United States
    • North Carolina
      • Greensboro, North Carolina, United States
    • Ohio
      • Kettering, Ohio, United States
    • Texas
      • Amarillo, Texas, United States
      • San Antonio, Texas, United States

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

All patients recruited for participation in study were indicated for continuous arrhythmia monitoring.

Description

Inclusion Criteria:

  • Patient is indicated for continuous arrhythmia monitoring with an Insertable Cardiac Monitor (ICM)
  • Patient is willing to undergo implant in clinic setting with only local anesthetic and/or oral anti-anxiety medications for sedation
  • Patient is 18 years of age or older
  • Patient is willing and able to provide consent and authorize the use and disclosure of health information
  • Patient is willing and able to comply with the protocol including the required follow-up

Exclusion Criteria:

  • Patient has reduced immune function or is otherwise at high risk for infection
  • Patient has had a recent (within 30 days) or otherwise unresolved infection
  • Patient is implanted or indicated for implant with a pacemaker, Implantable Cardioverter-Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT), or hemodynamic monitoring system
  • Patient is participating in another clinical study that may have an impact on the study endpoints
  • Patient's life expectancy is less than 1 year
  • Patient is pregnant
  • Patient has unusual thoracic anatomy or scarring at the implant site which may adversely affect the success of the implant procedure

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Procedure-related Complications Rate Requiring Resolution by Surgical Intervention
Time Frame: From Implant to 90 days post-implant procedure
This objective estimates the proportion of patients having procedure-related complication requiring resolution by surgical intervention at 90 days post-implant procedure using Kaplan-Meier method.
From Implant to 90 days post-implant procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants Having Procedure-related Adverse Events
Time Frame: From Implant to 90 days post-implant procedure
Report number of participants having procedure-related adverse events that meet the primary endpoint (requiring surgical intervention), and number of participants having other procedure-related adverse events (not requiring surgical intervention).
From Implant to 90 days post-implant procedure
Surgical Staff Utilized for Reveal In-office Implants
Time Frame: At implant
Observational analysis of surgical staff present at the Reveal Implants
At implant
Techniques and Procedures Utilized During Reveal In-office Implants
Time Frame: At implant
Observational data collection as to the technics and procedures utilized during all implants including (but not limited to): device orientation, suturing, wound closure, instrument and material use, and time.
At implant
Physician Satisfaction With Reveal In-office Implants
Time Frame: At implant
Observational survey of physicians satisfaction post implant At implant
At implant
R-wave Amplitude Measurement
Time Frame: Implant procedure and 30 days post-implant procedure
Average R-wave amplitude at implant and 30-days post procedure
Implant procedure and 30 days post-implant procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Reveal In-Office Implants Clinical Research Specialist, Medtronic

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2010

Primary Completion (Actual)

May 1, 2011

Study Completion (Actual)

May 1, 2011

Study Registration Dates

First Submitted

July 21, 2010

First Submitted That Met QC Criteria

July 21, 2010

First Posted (Estimate)

July 23, 2010

Study Record Updates

Last Update Posted (Actual)

February 28, 2018

Last Update Submitted That Met QC Criteria

January 30, 2018

Last Verified

January 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • Reveal In-Office Implants

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Arrhythmias, Cardiac

Clinical Trials on Reveal® DX or Reveal® XT Insertable Cardiac Monitor

3
Subscribe